You are here: Industry Insights > tumors

News List

Future Directions and Challenges to Desmoid Tumors and Nirogacestat David Orchard-Webb
January 07, 2025
Desmoid tumors, also known as aggressive fibromatosis, are uncommon non-metastatic soft tissue tumors distinguished by the proliferation of fibroblasts and myofibroblasts.
British Journal of Cancer: Zurletrectinib Is a Next-Generation TRK Inhibitor With Strong Intracranial Activity Against NTRK Fusion-Positive Tumors With On-Target Resistance to First-generation Agents July 31, 2024
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents.
An Emerging Target for Solid Tumors -- CD73 Development in China PharmaSources/Yefenghong
June 16, 2021
CD73, also known as Ecto-5′-Nucleotidase, is a cell surface enzyme, which is widely expressed on the surface of endothelial cells of human bodies, lymphocytes such as Treg and other cells.
Cell Therapy Expected to Treat Solid Tumors in the Future as a CAR-T cell Therapy Clinical Trial for Treating Gastric and Pancreatic Cancers was Accepted PharmaSources/Xiaobin
June 17, 2020
CAR-T cells can be easily led to cancer cells by relying on this target, to wipe out cancer. However, there is no such apparent target that only exists in tumor cells instead of normal cells in solid tumors.
Treovir Announces Opening of G207 Phase 2 Clinical Trial in Children with Recurrent Brain Tumors Biotech Newswire
December 05, 2024
Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in pediatric brain tumor patients.
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors PharmaSources
January 11, 2023
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market
Suppressing the spread of tumors WorldPharmaNews
February 09, 2022
Why some patients develop metastases and others do not is largely unclear. Researchers around ISTA professor Daria Siekhaus are now contributing to a better understanding of the process in certain types of cancer.
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors prnasia
January 10, 2022
Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors prnasia
January 06, 2022
Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial...
I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors prnasia
December 28, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the Center for Drug Evaluation...